Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

Psilocybin
News
Psilocybin May Improve Outcomes More Than Traditional MDD Treatments
10/08/2024
While intensive treatments with psilocybin and the serotonin reuptake inhibitor (SSRI) escitalopram were associated with long-term improvements in major depressive disorder (MDD) symptom severity, recent phase 2 double-blind, randomized,...
While intensive treatments with psilocybin and the serotonin reuptake inhibitor (SSRI) escitalopram were associated with long-term improvements in major depressive disorder (MDD) symptom severity, recent phase 2 double-blind, randomized,...
While intensive treatments with...
10/08/2024
Psych Congress Network
dr and patient with brain model
News
Rehospitalization Risk, Treatment Costs Lower With Continued/Maintenance ECT
10/08/2024
Continuing electroconvulsive therapy (ECT) after an acute ECT series is linked with lower rehospitalization risk compared with not continuing ECT, according to study results published in JAMA Psychiatry.
Continuing electroconvulsive therapy (ECT) after an acute ECT series is linked with lower rehospitalization risk compared with not continuing ECT, according to study results published in JAMA Psychiatry.
Continuing electroconvulsive...
10/08/2024
Psych Congress Network

Advertisement

A midlife woman sits on a couch and looks out the window with her chin resting on her fist.
News
Menopausal Hormone Therapy Benefits Midlife Women With Schizophrenia
10/04/2024
Menopausal hormone therapy (MHT) is associated with a 16% lower risk of psychosis relapse in midlife women with schizophrenia or schizoaffective disorder (SSD).
Menopausal hormone therapy (MHT) is associated with a 16% lower risk of psychosis relapse in midlife women with schizophrenia or schizoaffective disorder (SSD).
Menopausal hormone therapy (MHT)...
10/04/2024
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy.
News
Psilocybin Shows Potential for Depression Treatment, Meta-Analysis Finds
10/03/2024
High-dose psilocybin demonstrated an effect similar to escitalopram for the treatment of depressive symptoms in a recent systematic review and meta-analysis published in The BMJ.
High-dose psilocybin demonstrated an effect similar to escitalopram for the treatment of depressive symptoms in a recent systematic review and meta-analysis published in The BMJ.
High-dose psilocybin...
10/03/2024
Psych Congress Network
FDA approval featuring craig chepke
News
FDA Approves First Schizophrenia Treatment in Over 3 Decades
09/27/2024
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
The US Food and Drug...
09/27/2024
Psych Congress Network

Advertisement

News
Investigational Schizophrenia Drug Hits Primary Endpoint in Phase 2 Trial
09/26/2024
A once-daily, 20 mg dose of an investigational oral muscarinic M4 selective agonist in development for adults with schizophrenia achieved its primary endpoint in a phase 2 trial, maker Neurocrine Biosciences announced.
A once-daily, 20 mg dose of an investigational oral muscarinic M4 selective agonist in development for adults with schizophrenia achieved its primary endpoint in a phase 2 trial, maker Neurocrine Biosciences announced.
A once-daily, 20 mg dose of an...
09/26/2024
Psych Congress Network
a cartoon illustration of a man sitting on the floor with this hand on his head, looking distressed.
News
More Than a Fifth of Overdose Decedents Had Non–Substance Mental Health Disorder
09/23/2024
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths...
09/23/2024
Psych Congress Network
A woman sits on the floor looking sad and worried.
News
FDA OKs Digital Therapeutic for Generalized Anxiety Disorder
09/13/2024
The United States Food and Drug Administration (FDA) has granted clearance for DaylightRx, a prescription digital therapeutic designed to treat generalized anxiety disorder (GAD).
The United States Food and Drug Administration (FDA) has granted clearance for DaylightRx, a prescription digital therapeutic designed to treat generalized anxiety disorder (GAD).
The United States Food and Drug...
09/13/2024
Psych Congress Network

Advertisement

An elderly woman sits on a couch
News
Increasing Depression Symptoms in Older Adults Associated With Amyloid Accumulation
09/09/2024
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
brain netw
News
Patients With Specific Treatment-Resistant Depression Biotype Improve With TMS
09/05/2024
Patients with a particular cognitive biotype of treatment-resistant depression are more likely to experience improvement with TMS compared with other patients, study finds.
Patients with a particular cognitive biotype of treatment-resistant depression are more likely to experience improvement with TMS compared with other patients, study finds.
Patients with a particular...
09/05/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use